Abbott India
Market cap ₹54,122 Cr
- P/E
- 32.75
- Day range
- ₹25,400.00 – ₹25,950.00
- 52-week range
- ₹24,650.00 – ₹30,655.00
- Volume
- 6,603
- Open
- ₹25,865.00
- Prev close
- ₹25,815.00
Latest results · Q2 FY27(consolidated)Revenue ₹1,951 Cr+11.0%Profit ₹453 Cr+9.2%Margin 23.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
ABBOTINDIA in NSE indices and F&O
Research profile
Composite 67 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.1%
- Graham no.
- ₹5,820.55
- vs Graham
- -77.1%
- ROE ÷ P/B
- 2.6%
- 12-1 mom.
- -11.3%
- Return / vol
- -0.66
- Magic Formula
- #93
- Piotroski
- 5/5
- FCF yield
- 2.4%
- PEG
- 3.56
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Abbott IndiaABBOTINDIA | ₹54,122 Cr | 32.75 | 13.15 | 34.5% | 45.0% | 29.0% | 0.04 | +11.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1d agoHeadlines about Abbott India from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 34.1
- EPS (TTM)
- ₹777.85
- ROE (FY26)
- 34.5%
- ROCE (latest year)
- 45%
- Dividend yield
- 1.98%
Moving averages (NSE)
- 20-day
- ₹25,982.5
- Price below
- 50-day
- ₹26,150.8
- Price below
- 200-day
- ₹26,563.68
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 | 1,951 |
| Expenses | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 | 1,383 |
| Operating Profit | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 | 568 |
| OPM % | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% | 29% |
| Other Income | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 | 68 |
| Interest | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 | 6 |
| Depreciation | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 | 19 |
| Profit before tax | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 | 610 |
| Tax % | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% | 26% |
| Net Profit | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 | 453 |
| EPS in Rs | ₹146.35 | ₹135.09 | ₹154.36 | ₹168.76 | ₹169.78 | ₹172.73 | ₹172.18 | ₹195.43 | ₹176.93 | ₹185.86 | ₹201.66 | ₹213.40 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-2 days since Mar 2021 (S)
-16 days since Mar 2021 (S)
-7 days since Mar 2021 (S)
-11 days since Mar 2021 (S)
-2 days since Mar 2021 (S)
Strengths, risks & growth
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. [1] It was established in 1944. [2]
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 74.99% | 74.99% | 74.99% | 74.99% | 0.00 pp |
| FII | 0.19% | 0.27% | 0.38% | 0.40% | +0.02 pp |
| DII | 9.00% | 8.93% | 8.77% | 8.99% | +0.22 pp |
| Public | 15.83% | 15.81% | 15.85% | 15.62% | -0.23 pp |
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 7.55% (+0.11 pp)- Promoters75.0%
- Foreign institutions0.4%
- Mutual funds7.5%
- Insurance1.3%
- Other domestic institutions0.2%
- Retail13.1%
- Others2.5%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Large & Midcap Fund | 1.45% | 1.98% | -0.04 pp |
| Nippon India Multi Cap Fund | 0.75% | 0.79% | +0.16 pp |
| Axis Midcap Fund | 0.63% | 1.05% | -0.27 pp |
| Canara Rob Large and Mid Cap Fund | 0.62% | 1.39% | -0.02 pp |
| Nippon India Pharma Fund | 0.36% | 2.22% | -0.03 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 20.7%
- Downside volatility
- 18.7%
- Worst 5% of days
- 2.0%
- Average of that tail
- 2.6%
- Max drawdown (1Y)
- 19.2%
- Below its peak
- 17.8%
Against the market
- Beta vs Nifty 50
- 0.23
- Correlation
- 0.15
- Relative strength (3M)
- -9.2%
- ATR (14)
- 2.5%
Return
- Return 1M
- -2.7%
- Return 3M
- -5.3%
- Return 6M
- -8.8%
- Return 1Y
- -13.7%
- vs 200-day average
- -4.1%
Momentum
- RSI (14)
- 43.1
- MACD histogram
- -44.36
- Stochastic %K
- 3.4
- ADX (14)
- 15.0
- +DI / −DI
- 16.6 / 23.5
- Money flow index
- 45.7
Participation
- Delivery (20d avg)
- 56.0%
- vs its 60-day baseline
- +1.3 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.6%
- 52-week position
- 7 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 5 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — not testableneeds total income and expenses a year apart
- Asset turnover improving — passed
- Free cash flow
- ₹1,278 Cr
- FCF yield
- 2.4%
- Net debt
- -₹683 Cr
- Net debt / equity
- -0.16
- EV / sales
- 7.42
- PEG
- 3.56
- Revenue CAGR
- 11.0%
- Profit CAGR
- 9.2%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹525.00
Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share
24 Jul 2026ex-date - dividend₹475.00
Dividend - Rs 475 Per Share
25 Jul 2025ex-date - dividend₹410.00
Dividend - Rs 410 Per Share
19 Jul 2024ex-date - dividend₹180.00
Dividend - Rs 180 Per Share/ Special Dividend Rs 145 Per Share
21 Jul 2023ex-date - dividend₹145.00
Annual General Meeting/Dividend - Rs 145 Per Share/Special Dividend- 130 Per Share
2 Aug 2022ex-date - dividend₹120.00
Annual General Meeting/Dividend - Rs 120 Per Share Special Dividend 155 Per Share
19 Jul 2021ex-date - dividend₹107.00
Annual General Meeting/Dividend - Rs 107 Per Share And Special Dividend - Rs 143 Per Share
28 Aug 2020ex-date - dividend₹50.00
Annual General Meeting/ Final Dividend - Rs 50 Per Share/ Special Dividend - Rs 15 Per Share
13 Aug 2019ex-date - dividend₹50.00
Annual General Meeting / Final Dividend- Rs 50 Per Share / Special Dividend- Rs 5 Per Share
10 Jul 2018ex-date - dividend₹40.00
Annual General Meeting/Dividend Rs 40/- Per Share
10 Jul 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting/Divided - Rs 35/- Per Share
8 Jul 2016ex-date - dividend₹31.00
Annual General Meeting/Dividend - Rs 31/- Per Share
22 Jul 2015ex-date - dividend₹23.00
Annual General Meeting / Final Dividend - Rs 23/- Per Share
23 Jul 2014ex-date - dividend₹17.00
Annual General Meeting And Dividend Rs.17 Per Share
16 Apr 2013ex-date - dividend₹17.00
Annual General Meeting And Dividend Rs.17/- Per Share
4 May 2012ex-date - dividend₹17.00
Annual General Meeting / Final Dividend - Rs.17/- Per Share
19 Apr 2011ex-date - otherNot available — not reported in this filing
Agm/Div-Rs.17/- Per Share
3 Mar 2010ex-date
Company announcements
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.
Closure of Trading Window for declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2026.
Resignation of Company Secretary and Compliance Officer of the Company.
Voting Results along with Consolidated Scrutinizer's Report for the 82nd Annual General Meeting held on August 13, 2026.
Newspaper Publication
Proceedings of 82nd Annual General Meeting of the Company.
Unaudited financial results for the quarter ended June 30, 2026.
Outcome of Board Meeting
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities
Newspaper Advertisement for Eighty-second Annual General Meeting, E-voting facility and Dividend.
Communication providing the weblink including path of Annual Report.
Submission of Business Responsibility and Sustainability Report for the Financial Year 2025-26.
Notice of the 82nd Annual General Meeting of the Company to be held on August 13, 2026.
Filed with BSE (scrip 500488); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Buyback
Abbott India Limited
16 Jul 2008Read on SEBI - Buyback - Buyback
Abbott India Limited - Buyback
6 Mar 2007Read on SEBI - Buyback - Form of Acceptance
Abbott India Limited - Form of Acceptance
6 Mar 2007Read on SEBI - Open offer
Abbott India Limited
11 Oct 2006Read on SEBI
Regulatory orders
- Order
In the matter of Proposed Acquisition of voting rights of Abbott India Limited
17 Jun 2008Read on SEBI - Order
Order against M/s Abbott India Ltd
25 Jan 2007Read on SEBI
Documents
Annual reports
Earnings calls
- Sep 2022TranscriptRecording
- Jun 2021Transcript
Documents open at BSE or the rating agency that issued them.
Abbott India: common questions
Answered from the figures on this page.